💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vancomycin

CHEMBL262777 Phase 4 Aprobado Small molecule
Half-Life
4-6 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
1449.2 g/mol
LogP
-2.6
Phase
4

This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.

Peso molecular

1449,2500 g/mol

LogP

-2,60

TPSA

530,00 Ų

Regla de cinco de Lipinski

No cumple

Áreas terapéuticas

Artritis reumatoide Asma Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Diabetes tipo 2 Dolor crónico Enfermedad infecciosa Enfermedad inflamatoria intestinal Enfermedad renal crónica Epilepsia Esclerosis múltiple Esquizofrenia Hipertensión Insomnio Insuficiencia cardíaca Leucemia Linfoma Malaria Manejo del dolor Melanoma Migraña Obesidad Osteoporosis Trastorno bipolar Trastorno de ansiedad generalizada

Clases de fármacos

J — J - Antiinfecciosos de uso sistémico

Mecanismo de acción

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Pharmacokinetics (PK)

Half-Life 4-6 hours

Pharmacodynamics (PD)

Mecanismo

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C66H75Cl2N9O24

                    

                    
                    

                        
HBD / HBA

                        
19 / 26

                    

                    
                    

                        
Enlaces Rotables

                        
13

                    

                    
                    
                    

                        
Átomos Pesados

                        
101

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Vancomycin: Half-life: 4-6 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Vancomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amoxicillin
                            Small molecule
                        
                        
                        
                            Azithromycin
                            Small molecule
                        
                        
                        
                            Ciprofloxacin
                            Small molecule
                        
                        
                        
                            Doxycycline
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL262777.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 14969.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.